In order to evaluate potential synergistic effects with antibodies targeting other inhibitory ICs we investigated the biological effects of the novel anti-OX40 mAbs in combination with the clinically validated anti-PD-L1 mAb, Atezolizumab, in co-cultures of hPBMCs and tumor cells. The gene discussed is TNFRSF4; the disease is neoplasm.